Publications

Our scientific output and findings

From groundbreaking discoveries in basic science to innovative clinical insights, our publications showcase the breadth and depth of research taking place at the UK DRI. 

Featured

Cytokines released by T cells after encountering cancer cells

A balancing act: preventing an overactive immune system

Research into an immune kill switch holds potential for controlling infections or preventing autoimmunity. The study, led by Prof Jernej Ule (UK DRI at King's)...

Learn more A balancing act: preventing an overactive immune system
Sci Adv
Published

Incomplete annotation has a disproportionate impact on our understanding of Mendelian and complex neurogenetic disorders.

Authors
David Zhang, Sebastian Guelfi, Sonia Garcia-Ruiz, Beatrice Costa, Regina H Reynolds, Karishma D'Sa, Wenfei Liu, Thomas Courtin, Amy Peterson, Andrew E Jaffe, John Hardy, Juan A Botía, Leonardo Collado-Torres, Mina Ryten
Incomplete annotation has a disproportionate impact on our understanding of Mendelian and complex neurogenetic disorders.
Sci Adv
Published

Incomplete annotation has a disproportionate impact on our understanding of Mendelian and complex neurogenetic disorders.

Authors
David Zhang, Sebastian Guelfi, Sonia Garcia-Ruiz, Beatrice Costa, Regina H Reynolds, Karishma D'Sa, Wenfei Liu, Thomas Courtin, Amy Peterson, Andrew E Jaffe, John Hardy, Juan A Botía, Leonardo Collado-Torres, Mina Ryten
Incomplete annotation has a disproportionate impact on our understanding of Mendelian and complex neurogenetic disorders.
Nat Genet
Published

Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease.

Authors
Julien Bryois, Nathan G Skene, Thomas Folkmann Hansen, Lisette J A Kogelman, Hunna J Watson, Zijing Liu, Leo Brueggeman, Gerome Breen, Cynthia M Bulik, Ernest Arenas, Jens Hjerling-Leffler, Patrick F Sullivan
Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease.
Brain
Published

Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.

Authors
Maura Malpetti, Rogier A Kievit, Luca Passamonti, P Simon Jones, Kamen A Tsvetanov, Timothy Rittman, Elijah Mak, Nicolas Nicastro, W Richard Bevan-Jones, Li Su, Young T Hong, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Rowe
Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Brain
Published

Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.

Authors
Maura Malpetti, Rogier A Kievit, Luca Passamonti, P Simon Jones, Kamen A Tsvetanov, Timothy Rittman, Elijah Mak, Nicolas Nicastro, W Richard Bevan-Jones, Li Su, Young T Hong, Tim D Fryer, Franklin I Aigbirhio, John T O'Brien, James B Rowe
Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Nat Genet
Published

Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease.

Authors
Julien Bryois, Nathan G Skene, Thomas Folkmann Hansen, Lisette J A Kogelman, Hunna J Watson, Zijing Liu, , , , Leo Brueggeman, Gerome Breen, Cynthia M Bulik, Ernest Arenas, Jens Hjerling-Leffler, Patrick F Sullivan
Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease.
Lancet Neurol
Published

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Authors
Jeremy Chataway, Floriana De Angelis, Peter Connick, Richard A Parker, Domenico Plantone, Anisha Doshi, Nevin John, Jonathan Stutters, David MacManus, Ferran Prados Carrasco, Frederik Barkhof, Sebastien Ourselin, Marie Braisher, Moira Ross, Gina Cranswick, Sue H Pavitt, Gavin Giovannoni, Claudia Angela Gandini Wheeler-Kingshott, Clive Hawkins, Basil Sharrack, Roger Bastow, Christopher J Weir, Nigel Stallard, Siddharthan Chandran,
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.